The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Boston Scientific's revenues will contract -4.7% and EPS will increase 37.5%.
The average estimate for revenue is $1.76 billion. On the bottom line, the average EPS estimate is $0.11.
Last quarter, Boston Scientific chalked up revenue of $1.74 billion. GAAP reported sales were 7.4% lower than the prior-year quarter's $1.87 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.10. GAAP EPS were -$0.48 for Q3 compared to $0.09 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 66.2%, 400 basis points better than the prior-year quarter. Operating margin was 14.1%, 290 basis points better than the prior-year quarter. Net margin was -38.3%, 4,590 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $7.19 billion. The average EPS estimate is $0.41.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 748 members out of 933 rating the stock outperform, and 185 members rating it underperform. Among 190 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 169 give Boston Scientific a green thumbs-up, and 21 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.10.
Is Boston Scientific the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Boston Scientific to My Watchlist.